RT Journal Article
SR Electronic
T1 Interplay Between the Gut Microbiome and Typhoid Fever: Insights from Endemic Countries and a Controlled Human Infection Model
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.02.24312347
DO 10.1101/2024.09.02.24312347
A1 Ashton, Philip M.
A1 Mageiros, Leonardos
A1 Meiring, James E.
A1 Chirambo, Angeziwa Chunga
A1 Khanam, Farhana
A1 Banda, Happy
A1 Karkey, Abhilasha
A1 Dongol, Sabina
A1 Llanes, Lorena Preciado
A1 Thomaides-Brears, Helena
A1 Gibani, Malick
A1 Rajib, Nazmul Hasan
A1 Rahman, Nazia
A1 Biswas, Prasanta Kumar
A1 Islam Bhuiyan, Md Amirul
A1 Kay, Sally
A1 Auger, Kate
A1 Seret, Olivier
A1 Thomson, Nicholas R.
A1 Pollard, Andrew J
A1 Baker, Stephen
A1 Basnyat, Buddha
A1 Clemens, John D.
A1 Dolecek, Christiane
A1 Dunstan, Sarah J.
A1 Dougan, Gordon
A1 Heyderman, Robert S.
A1 Pitzer, Virginia E.
A1 Qadri, Firdausi
A1 Gordon, Melita A.
A1 Darton, Thomas C.
A1 Holt, Kathryn E.
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/09/03/2024.09.02.24312347.abstract
AB Typhoid fever is a systemic infection caused by Salmonella enterica serovar Typhi (S. Typhi) bacteria invading through the gut lumen. Transmission occurs through ingestion of contaminated food and water, particularly in settings with poor water, sanitation and hygiene infrastructure, resulting in over 10 million illnesses annually. It is well established that vaccines and natural infections can stimulate protective immunity against S. Typhi. As the pathogen invades through the gastrointestinal tract, it is plausible that the gut microbiome may also influence the outcome of S. Typhi exposure. There is some evidence that bacteria producing short-chain fatty acids (SCFAs) may create an environment unfavourable to invasive Salmonella, but data from humans is very limited.To investigate the association between gut microbiome and typhoid fever, we analysed samples collected from three all-age cohorts recruited in a prospective surveillance study conducted in parallel in three settings where typhoid fever is endemic (Dhaka, Bangladesh; Blantyre, Malawi; and Kathmandu, Nepal). Cohorts consisted of acute typhoid fever patients (n=92), asymptomatic household contacts of typhoid fever patients (representing individuals who were likely exposed to S. Typhi but did not develop disease, n=97), and asymptomatic serosurvey participants with high Vi antibody titres (representing individuals who were exposed to S. Typhi and may be carriers, n=69). The stool microbiomes of each cohort were characterised using shotgun metagenomics, and bacterial composition and diversity were compared.We identified four bacterial species and 28 metabolic gene clusters (MGCs) that were significantly lower in abundance in typhoid fever patients compared with household contacts (i.e. probably exposed), in two of the three host populations (Bangladesh and Malawi). These may represent taxa that provide protection against development of clinical infection upon exposure to S. Typhi, and include the inflammation-associated species Prevotella copri clade A and Haemophilus parainfluenzae, and seven MGCs involved in SCFA metabolism. The putative protection provided by SCFA metabolism was supported by data from a controlled human infection model conducted in a UK population, in which participants who did not develop typhoid fever following ingestion of S. Typhi had significantly higher abundance of a putative SCFA-metabolising MGC (q-value = 0.22).This study identified the same associations between taxonomic and functional microbiota characteristics and non-susceptibility to typhoid fever across multiple cohorts. Future research should explore the potential functional role of SCFAs and inflammation-associated bacteria in resistance to S. Typhi and other enteric infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKA, SK, NRT, OS were funded by the Wellcome Trust (220540/Z/20/A). For the purpose of open access, the authors have applied a CC-BY public copyright licence to any author-accepted manuscript version arising from this submission. This research was funded by the Wellcome Trust (STRATAA grant number 106158/Z/14/Z, and core funding to the Wellcome Sanger Institute, grant number 206194) and the Bill & Melinda Gates Foundation (grant number OPP1141321). MAG, ACC, and PMA were supported by a research professorship (NIHR300039) from the National Institute for Health and Care Research, UK Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by the Oxford Tropical Research Ethics Committee (University of Oxford, Oxford, UK).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yeshttps://github.com/flashton2003/STRATAA_metagenomics